<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011268</url>
  </required_header>
  <id_info>
    <org_study_id>HMR2016-0.6</org_study_id>
    <secondary_id>2016-001409-18</secondary_id>
    <nct_id>NCT03011268</nct_id>
  </id_info>
  <brief_title>Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?</brief_title>
  <acronym>BIOSTOP</acronym>
  <official_title>Continuing or Discontinuing Anti-tumor Necrosis Factor Treatment in Patients With Ulcerative Colitis in Clinical Remission: a Prospective Open Randomized Parallel-group Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Møre og Romsdal HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Oslo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Møre og Romsdal HF</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess if discontinuation of anti- tumor necrosis factor alpha
      (TNF) treatment in ulcerative colitis patients in sustained clinical remission, with the
      option to restart treatment in the case of relapse, is non-inferior to continued anti-TNF
      treatment. Secondary objectives are to assess the efficacy and safety of restarting anti-TNF
      treatment after a relapse
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BIOSTOP study is a prospective, open randomized, multicenter, parallel-group study to
      compare clinical outcome of discontinuing (interventional group) compared to continuing
      (control group) biologic treatment with anti-TNF in ulcerative colitis patients in clinical
      remission.

      Adult male and female patients with an established diagnosis of ulcerative colitis treated
      for minimum one year with anti-TNF maintenance therapy and being in clinical remission during
      the last 3 months are potential study patients. Eligible patients who have given their
      informed written consent will be randomized 1:1 to either discontinue anti-TNF treatment or
      to continue anti-TNF treatment for another two years.

      Patients in the control group who are still in clinical and endoscopic remission after two
      years on continued anti-TNF treatment, will then be switched to discontinue anti-TNF
      treatment.

      End of study/follow-up is after 4 years. In order to identify the primary endpoint
      (occurrence of disease relapse), each study center will have a phone number for patients to
      call in case of symptoms suspect of increased disease activity. If a patient is experiencing
      a potential disease flare (6-point Mayo score &gt; 1) and/or 2 consecutive calprotectin tests
      are positive (&gt; 200 mg/kg), an unscheduled visit including recto sigmoidoscopy will be
      performed without delay to document disease status.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in sustained clinical remission</measure>
    <time_frame>2 years</time_frame>
    <description>Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 2 years of randomized treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in sustained clinical remission</measure>
    <time_frame>4 years</time_frame>
    <description>Remission confirmed endoscopically by mucosal healing defined as Mayo Endoscopic Subscore (MES) score 0 or 1 after 4 years of randomized treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to relapse</measure>
    <time_frame>2 years</time_frame>
    <description>Relapse time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to relapse</measure>
    <time_frame>4 years</time_frame>
    <description>Relapse time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy</measure>
    <time_frame>2 years</time_frame>
    <description>Remission, but no need to restart anti-tnf therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who are no longer in remission, but who do not need to restart anti-tumor necrosis factor (TNF) therapy</measure>
    <time_frame>4 years</time_frame>
    <description>Remission, but no need to restart anti-tnf therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of relapse patients achieving remission after anti-TNF restart</measure>
    <time_frame>2 years</time_frame>
    <description>Remission after relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of relapse patients achieving remission after anti-TNF restart</measure>
    <time_frame>4 years</time_frame>
    <description>Remission after relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events frequency and severity</measure>
    <time_frame>2 years</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events and serious adverse events frequency and severity</measure>
    <time_frame>4 years</time_frame>
    <description>Adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colitis,Ulcerative</condition>
  <arm_group>
    <arm_group_label>Anti TNF discontinuation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Discontinuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anti TNF continuation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuation of anti-TNF treatment (Infliximab, Adalimumab, Golimumab)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Discontinuation of anti-TNF treatment</intervention_name>
    <description>Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences</description>
    <arm_group_label>Anti TNF discontinuation</arm_group_label>
    <other_name>Remicade, Remsima, Inflectra, Humira, Simponi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Continuation of anti-TNF treatment</intervention_name>
    <description>Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue</description>
    <arm_group_label>Anti TNF continuation</arm_group_label>
    <other_name>Remicade, Remsima, Inflectra, Humira, Simponi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed diagnosis of ulcerative colitis

          -  treated for minimum 1 year with first-line anti-tumor necrosis factor (TNF) treatment

          -  in sustained clinical remission during the last 3 months

          -  capable of understanding and signing an informed consent form

        Exclusion Criteria:

          -  Discontinuation of systemic 5-Aminosalicylic acid (ASA) or immunomodulatory therapy or
             other medication that could affect disease activity during the last 3 months prior to
             randomization

          -  Any treatment of systemic corticosteroids due to disease exacerbation during the last
             3 months (i.e. patients being in steroid free clinical remission)

          -  Patients on anti-TNF monotherapy with intolerance to both 5-ASA and immunomodulatory
             therapy

          -  Change in the anti-TNF treatment during the last 3 months due to disease related
             factors, not including dose/frequency adjustments due to drug concentration
             measurements

          -  Use of any second-line anti-TNF medication irrespective of reason for stopping
             first-line anti-TNF

          -  Previous failed attempts of anti-TNF discontinuation of more than 4 months' duration,
             with the exception of discontinuation due to pregnancy

          -  Detection of anti-TNF antibodies in moderate-high titers prior to randomization

          -  Psychiatric or mental disorders

          -  Alcohol abuse or other substance abuse

          -  language barriers or other factors which makes adherence to the study protocol
             impossible

          -  Participation in any other studies

          -  pregnancy

          -  breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dag Arne L Hoff, md, phd</last_name>
    <role>Study Director</role>
    <affiliation>Helse Møre og Romsdal Hospital Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dag Arne L Hoff, md, phd</last_name>
    <phone>+ 4770105000</phone>
    <email>Dag.Arne.Lihaug.Hoff@helse-mr.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ingrid P Berset, md</last_name>
    <phone>+4770105000</phone>
    <email>Ingrid.Prytz.Berset@helse-mr.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Helse Møre og Romsdal, Ålesund Sjukehus</name>
      <address>
        <city>Alesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sørlandet Sykehus HF, Arendal</name>
      <address>
        <city>Arendal</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus Helse Bergen HF</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nordlandssykehuset HF, Bodø</name>
      <address>
        <city>Bodo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vestre Viken HF, Drammen Sykehus</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helse Førde, Førde Sentralsjukehus</name>
      <address>
        <city>Forde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sykehuset Østfold HF Kalnes</name>
      <address>
        <city>Fredrikstad</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet, Gjøvik Sykehus</name>
      <address>
        <city>Gjovik</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet, Hamar Sykehus</name>
      <address>
        <city>Hamar</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset i Nord-Norge, Harstad</name>
      <address>
        <city>Harstad</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sørlandet Sykehus HF, Kristiansand</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helse Møre og Romsdal, Kristiansund Sjukehus</name>
      <address>
        <city>Kristiansund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helse Nord Trøndelag, Levanger Sykehus</name>
      <address>
        <city>Levanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sykehuset Innlandet, Lillehammer Sykehus</name>
      <address>
        <city>Lillehammer</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus, Lørenskog</name>
      <address>
        <city>Lørenskog</city>
        <zip>1478</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helse Møre og Romsdal, Molde Sjukehus</name>
      <address>
        <city>Molde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helse Nord Trøndelag, Namsos Sykehus</name>
      <address>
        <city>Namsos</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lovisenberg Diakonale sykehus</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus, Rikshospitalet</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oslo Universitetssykehus, Ullevål</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vestre Viken HF, Bærum Sykehus</name>
      <address>
        <city>Sandvika</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sykehuset Telemark, Skien</name>
      <address>
        <city>Skien</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stavanger Universitetssykehus</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sykehuset Vestfold, Tønsberg</name>
      <address>
        <city>Tonsberg</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset i Nord-Norge, Tromsø</name>
      <address>
        <city>Tromso</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helse Møre og Romsdal, Volda Sjukehus</name>
      <address>
        <city>Volda</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helse Bergen HF Voss Sjukehus</name>
      <address>
        <city>Voss</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Molander P, Färkkilä M, Ristimäki A, Salminen K, Kemppainen H, Blomster T, Koskela R, Jussila A, Rautiainen H, Nissinen M, Haapamäki J, Arkkila P, Nieminen U, Kuisma J, Punkkinen J, Kolho KL, Mustonen H, Sipponen T. Does fecal calprotectin predict short-term relapse after stopping TNFα-blocking agents in inflammatory bowel disease patients in deep remission? J Crohns Colitis. 2015 Jan;9(1):33-40. doi: 10.1016/j.crohns.2014.06.012.</citation>
    <PMID>25052347</PMID>
  </reference>
  <reference>
    <citation>Gisbert JP, Marín AC, Chaparro M. Systematic review: factors associated with relapse of inflammatory bowel disease after discontinuation of anti-TNF therapy. Aliment Pharmacol Ther. 2015 Aug;42(4):391-405. doi: 10.1111/apt.13276. Epub 2015 Jun 15. Review.</citation>
    <PMID>26075832</PMID>
  </reference>
  <reference>
    <citation>Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology. 2015 Dec;149(7):1716-30. doi: 10.1053/j.gastro.2015.08.055. Epub 2015 Sep 14. Review.</citation>
    <PMID>26381892</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2017</study_first_submitted>
  <study_first_submitted_qc>January 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>March 16, 2018</last_update_submitted>
  <last_update_submitted_qc>March 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tumor Necrosis Factor-alpha/antagonists &amp; inhibitors</keyword>
  <keyword>Infliximab</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Golimumab</keyword>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>At this time there is no such plan for IPD sharing. It might be an issue regarding material stored in the study Biobank - that will be elucidated at a later stage.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

